Company profile TARS

Tarsus Pharmaceuticals Inc
tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland dis...ease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california. Show More
Quarter analysis & expected interestLast update: February 09 2024 19:23:11.

After 39 days of this quarter the interest is at 72.0. Based on that we can calculate that during remaining 52 days it will total up to 168.0.
Tarsus Pharmaceuticals expected interest is significantly lower compared to same quarter last year (-56.2%) but similar to previous quarter.

YearQ1Q2Q3Q4
201915
33
120.0% QoQ
28
-15.2% QoQ
105
275.0% QoQ
2020 21
40.0% YoY -80.0% QoQ
114
245.5% YoY 442.9% QoQ
145
417.9% YoY 27.2% QoQ
163
55.2% YoY 12.4% QoQ
2021 120
471.4% YoY -26.4% QoQ
160
40.4% YoY 33.3% QoQ
80
-44.8% YoY -50.0% QoQ
164
0.6% YoY 105.0% QoQ
2022 153
27.5% YoY -6.7% QoQ
135
-15.6% YoY -11.8% QoQ
108
35.0% YoY -20.0% QoQ
137
-16.5% YoY 26.9% QoQ
2023 384
151.0% YoY 180.3% QoQ
337
149.6% YoY -12.2% QoQ
372
244.4% YoY 10.4% QoQ
232
69.3% YoY -37.6% QoQ
2024 72
-81.2% YoY -69.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Tarsus Pharmaceuticals search interestLast update: February 09 2024 19:23:10.
Correlation coefficient between keyword and revenue is -0.29
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 19:23:12.

The average 5 years interest of Tarsus Pharmaceuticals was 11.79 per week.
The last year interest of Tarsus Pharmaceuticals compared to the last 5 years has changed by 108.14%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 532.47%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals TP-03 to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals TP-03 search interest

There is not enough data for Tarsus Pharmaceuticals TP-03 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals TP-03 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals TP-04 to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals TP-04 search interest

There is not enough data for Tarsus Pharmaceuticals TP-04 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals TP-04 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals TP-05 to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals TP-05 search interest

There is not enough data for Tarsus Pharmaceuticals TP-05 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals TP-05 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals lotilaner to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals lotilaner search interest

There is not enough data for Tarsus Pharmaceuticals lotilaner to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals lotilaner to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals blepharitis treatment to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals blepharitis treatment search interest

There is not enough data for Tarsus Pharmaceuticals blepharitis treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals blepharitis treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals meibomian gland disease treatment to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals meibomian gland disease treatment search interest

There is not enough data for Tarsus Pharmaceuticals meibomian gland disease treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals meibomian gland disease treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals rosacea treatment to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals rosacea treatment search interest

There is not enough data for Tarsus Pharmaceuticals rosacea treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals rosacea treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals Lyme prophylaxis to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals Lyme prophylaxis search interest

There is not enough data for Tarsus Pharmaceuticals Lyme prophylaxis to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals Lyme prophylaxis to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tarsus Pharmaceuticals community malaria reduction to provide analysis

Correlation between past revenue and Tarsus Pharmaceuticals community malaria reduction search interest

There is not enough data for Tarsus Pharmaceuticals community malaria reduction to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tarsus Pharmaceuticals community malaria reduction to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TARS
Earnings date: 2024-03-11 After close
Company name: Tarsus Pharmaceuticals Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T12:30:00Z

GlobeNewswire
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

2026-05-07T21:00:00Z

GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences

2026-05-06T20:05:00Z

GlobeNewswire
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

2026-05-04T10:10:45Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target

2026-04-29T20:30:00Z

GlobeNewswire
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

2026-03-31T12:30:00Z

GlobeNewswire
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

2026-03-23T12:30:00Z

GlobeNewswire
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

2026-02-26T21:30:00Z

GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences

2026-02-25T17:44:54Z

Analyst Upgrades
Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $105

2026-02-25T14:24:43Z

Analyst Upgrades
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $90

2026-02-23T21:05:00Z

GlobeNewswire
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

2026-02-18T13:30:00Z

GlobeNewswire
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

2026-02-17T21:30:00Z

GlobeNewswire
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

2025-12-09T16:19:04Z

Analyst Upgrades
Barclays Initiates Coverage On Tarsus Pharmaceuticals with Overweight Rating, Announces Price Target of $100

2025-11-24T21:30:00Z

GlobeNewswire
Tarsus to Participate in Upcoming Investor Conference